Gemcitabine

Catalog No.S1714

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Price Stock Quantity  
USD 130 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11NHj3[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDHWopKSzVyPUCuNFAxPDV6IH7NNGr4O|FUSU6JRWK=
ES4NFjYRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfhNXM{UUN3ME2wMlAxODZ3MzDuUS=>NITFOGFUSU6JRWK=
ACHNMlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXHeHBKSzVyPUCuNFAxQDh5IH7NMnLYV2FPT0WU
KYSE-510NFj5V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XCemlEPTB;MD6wNFA6PzVibl2=MorGV2FPT0WU
EW-7NYe0PI9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;C[45YUUN3ME2wMlAxOjV6IH7NNGLR[mpUSU6JRWK=
BFTC-905NHi4V|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{i0WGlEPTB;MD6wNFUyPSCwTR?=M4LVUnNCVkeHUh?=
KE-37MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwMEC1OlEhdk1?NWqy[HNZW0GQR1XS
SBC-5MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTBwMEC1O{BvVQ>?M{XnOXNCVkeHUh?=
NKM-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlm4TWM2OD1yLkCwO|A6KG6PM2jpRnNCVkeHUh?=
RH-1NGXSR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFT1XZBKSzVyPUCuNFA4OThibl2=MmC0V2FPT0WU
ALL-POM3TFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr6TWM2OD1yLkCwPFMhdk1?MkP5V2FPT0WU
QIMR-WILM4X3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMEC4PVQhdk1?NIHUOnJUSU6JRWK=
A375NI[yO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33I[mlEPTB;MD6wNFk6PSCwTR?=M3jVWnNCVkeHUh?=
SIG-M5NWrkcFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwMEGwOEBvVQ>?MoLYV2FPT0WU
KGNM1n3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPQSnU{UUN3ME2wMlAyODhibl2=NYXpUWR6W0GQR1XS
EW-13M4n5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjYUWM4UUN3ME2wMlAyOTJibl2=NUm4S5dMW0GQR1XS
NCI-SNU-1MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XYc2lEPTB;MD6wNVYhdk1?MoXJV2FPT0WU
PSN1NXrBWGFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;nTIxpUUN3ME2wMlAyPjVibl2=MlTPV2FPT0WU
HUTU-80MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTBwMEG2OkBvVQ>?NE\2eYlUSU6JRWK=
EW-16MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwMEKzJI5ONF\hTnhUSU6JRWK=
786-0NF3TcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fFfmlEPTB;MD6wNlMhdk1?MoXQV2FPT0WU
ES1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFSwcHFKSzVyPUCuNFI3QCCwTR?=MnfyV2FPT0WU
RKONVroZ4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwMEK3PUBvVQ>?MXXTRW5ITVJ?
ESS-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[4TWM2OD1yLkCyPFYhdk1?NV7V[3FzW0GQR1XS
SK-UT-1M37yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoriTWM2OD1yLkCyPVchdk1?NFnMUpRUSU6JRWK=
LB2241-RCCM2OwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XtUGlEPTB;MD6wN|E5KG6PNV7JOIdCW0GQR1XS
CHL-1NEnlWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfSR4FKSzVyPUCuNFMzPCCwTR?=MkXvV2FPT0WU
SW1783MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwMEOzOkBvVQ>?Mnr1V2FPT0WU
MEL-JUSOM2juOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M163d2lEPTB;MD6wN|kyKG6PNF\aN4NUSU6JRWK=
HT-29NGfmOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjYUpJoUUN3ME2wMlA1OTNibl2=NWHieVNxW0GQR1XS
SNG-MMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwMESyOUBvVQ>?Ml3zV2FPT0WU
TE-15NGf4S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HCW2lEPTB;MD6wOFY1KG6PNHL1O41USU6JRWK=
HOSNXnv[oV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfpPWtKSzVyPUCuNFQ5KG6PM2fERnNCVkeHUh?=
BB65-RCCNVvsbINnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1W0SmlEPTB;MD6wOVEzKG6PNWmxbY5bW0GQR1XS
HCE-4NH73RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3QTHlIUUN3ME2wMlA2Ojhibl2=MWHTRW5ITVJ?
MHH-ES-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIj1dldKSzVyPUCuNFU{OSCwTR?=NV7OOFhuW0GQR1XS
RPMI-7951NIXQR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHUTWM2OD1yLkC1OFEhdk1?M1PmXXNCVkeHUh?=
IST-SL2MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;1fnd4UUN3ME2wMlA2QDRibl2=M17lN3NCVkeHUh?=
CMKNYDz[ms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTBwMEW4OkBvVQ>?MXHTRW5ITVJ?
GR-STM1XJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPKTWM2OD1yLkC1PVUhdk1?MYTTRW5ITVJ?
NALM-6NETnfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn72TWM2OD1yLkC2NlIhdk1?NEjER2FUSU6JRWK=
RPMI-6666MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[zXIZKSzVyPUCuNFY2OiCwTR?=NFvwZ4NUSU6JRWK=
LC-2-adMmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3KzTWlEPTB;MD6wOlU{KG6PMXvTRW5ITVJ?
ARH-77M4LXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofGTWM2OD1yLkC3NVEhdk1?NGLIe5RUSU6JRWK=
IST-MEL1M2\5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwMEeyOkBvVQ>?NYPjb5hsW0GQR1XS
SW1710MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\GZY1zUUN3ME2wMlA4PTFibl2=M{\pc3NCVkeHUh?=
DELNEPR[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTBwMEi4O{BvVQ>?MX3TRW5ITVJ?
AGSM{PPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfxTWM2OD1yLkC5NFIhdk1?NVnSSHlTW0GQR1XS
NCI-H2122M3XtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwMEm0OkBvVQ>?NWj4OWVuW0GQR1XS
HSC-4NH7QPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlH0TWM2OD1yLkGwNkBvVQ>?M4KycXNCVkeHUh?=
AM-38Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH4TWM2OD1yLkGyNUBvVQ>?NEXWdYJUSU6JRWK=
769-PM1m5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPSTWM2OD1yLkGyN{BvVQ>?M4\tOHNCVkeHUh?=
RT-112MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXYTWM2OD1yLkGyO{BvVQ>?NXW4cZVuW0GQR1XS
MCF7MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwMUO2JI5OMWnTRW5ITVJ?
IGROV-1NHnKc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmj0TWM2OD1yLkG0OUBvVQ>?M3TXNXNCVkeHUh?=
OCI-AML2NF3Z[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfoTWM2OD1yLkG0O{BvVQ>?NF75Xo1USU6JRWK=
NCI-H1299MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETXOZFKSzVyPUCuNVU4KG6PMYjTRW5ITVJ?
A431MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\wTWM2OD1yLkG4N{BvVQ>?NUnkPGh{W0GQR1XS
SW982NYr2VGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHiyOldKSzVyPUCuNlE{KG6PMVLTRW5ITVJ?
BB30-HNCMormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwMkOxJI5OMYDTRW5ITVJ?
ACNMonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmX3TWM2OD1yLkK0OEBvVQ>?Moj0V2FPT0WU
647-VNWLvVZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[wNmlEPTB;MD6yOFghdk1?MXTTRW5ITVJ?
SK-PN-DWNUDEd4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTBwMk[2JI5OM3z2TXNCVkeHUh?=
LCLC-97TM1M4jweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwMk[3JI5ONYj4fW5mW0GQR1XS
LB1047-RCCM{DXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWCxZnNNUUN3ME2wMlI3QSCwTR?=MUPTRW5ITVJ?
A2780MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWX0O3I6UUN3ME2wMlI4KG6PM3j0fXNCVkeHUh?=
C-33-AMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfLTWM2OD1yLkK3N{BvVQ>?NIjwZopUSU6JRWK=
NCI-H2228NInYVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4O3WmlEPTB;MD6zNVQhdk1?M4LOeHNCVkeHUh?=
TE-5Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXqS5psUUN3ME2wMlMyPiCwTR?=NGC3WHdUSU6JRWK=
HC-1NVrTdpFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwM{K3JI5OM{\wc3NCVkeHUh?=
SK-MES-1Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nkV2lEPTB;MD6zNlghdk1?NXm4TGVrW0GQR1XS
NCI-H1355MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHk[|lKSzVyPUCuN|gyKG6PNV;0bJh2W0GQR1XS
YKG-1MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwNEG5JI5OMmjYV2FPT0WU
RS4-11NW\OPXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK4boFKSzVyPUCuOFM{KG6PNWeyRocxW0GQR1XS
DaoyNYTyZ4J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUS0clJLUUN3ME2wMlQ2PiCwTR?=M{\s[XNCVkeHUh?=
A3-KAWNIXjWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\0eZdOUUN3ME2wMlU2OSCwTR?=NHzuS2lUSU6JRWK=
SK-MEL-30MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTBwNUW0JI5OMoPEV2FPT0WU
U031NFyxWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn31TWM2OD1yLkW2OUBvVQ>?NVWze3kyW0GQR1XS
SK-LMS-1NVyyUYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwNUe4JI5ONFH3bY9USU6JRWK=
ES6MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDFTWM2OD1yLkW4OkBvVQ>?NXvJRWtoW0GQR1XS
EoL-1-cellMlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLhPYRKSzVyPUCuOlE3KG6PM4P3WXNCVkeHUh?=
NCI-H2009MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH25fYdKSzVyPUCuOlE6KG6PMYjTRW5ITVJ?
A4-FukM2Lmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4H4SmlEPTB;MD62NlYhdk1?MWLTRW5ITVJ?
KYSE-270NULpTJVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HKUWlEPTB;MD62N|Qhdk1?NEnrXVBUSU6JRWK=
SK-LU-1NYDRdG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrBTWM2OD1yLk[1OUBvVQ>?NUTOUJAyW0GQR1XS
SW872M2HqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rLTGlEPTB;MD63OlUhdk1?MkHqV2FPT0WU
ES8NUDTdJlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTBwN{igcm0>NYXRWZJEW0GQR1XS
G-402MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLiNnJKSzVyPUCuO|g1KG6PNXzzZVRoW0GQR1XS
ATN-1NHO3[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XxVWlEPTB;MD64NFchdk1?MY\TRW5ITVJ?
DoTc2-4510MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3W0cmlEPTB;MD65NFEhdk1?NHrEPY5USU6JRWK=
MES-SANV3F[4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HNSmlEPTB;MD65NFUhdk1?MlPUV2FPT0WU
SF268MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwOUK3JI5OM4n0[HNCVkeHUh?=
SF539M1u3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\0Z2lEPTB;MT6wNkBvVQ>?Ml;oV2FPT0WU
NB69M3jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3n5fmlEPTB;MT6wOUBvVQ>?NVXqSGJuW0GQR1XS
8505CMn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTFwME[gcm0>M4qwenNCVkeHUh?=
CAL-12TM2jHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPSTWM2OD1zLkC4JI5OMmWyV2FPT0WU
BHYMkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHNTWM2OD1zLkG0JI5OMoK4V2FPT0WU
LB647-SCLCM4LWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XuWGlEPTB;MT6xPEBvVQ>?M2rwW3NCVkeHUh?=
CAL-62NGrHdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7rTWM2OD1zLkKyJI5ONV61bZNiW0GQR1XS
MEG-01MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFO2[G9KSzVyPUGuNlchdk1?MU\TRW5ITVJ?
MG-63NYm0UXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWX0VGFHUUN3ME2xMlM{KG6PMlrwV2FPT0WU
SW620NH:5dZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTFwM{Wgcm0>MWPTRW5ITVJ?
A388NYfTbFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nPPWlEPTB;MT6zOkBvVQ>?NU\CZ|hYW0GQR1XS
BCPAPMmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfKSYFKSzVyPUGuOFUhdk1?MkfSV2FPT0WU
P30-OHKM2X5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIqwO41KSzVyPUGuOFYhdk1?NF;rVY1USU6JRWK=
Ca9-22NX;hWZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXwUWhKSzVyPUGuOVQhdk1?MUfTRW5ITVJ?
VMRC-RCZNHzES29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[4c|hKSzVyPUGuOVQhdk1?M2HYbnNCVkeHUh?=
LOXIMVIMlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\pPWlEPTB;MT62JI5OMlLDV2FPT0WU
L-540MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfBSWU5UUN3ME2xMlYhdk1?MoHkV2FPT0WU
NTERA-S-cl-D1NVPIcXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTFwNkSgcm0>NIjlW5lUSU6JRWK=
MFH-inoMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnabplKSzVyPUGuOlYhdk1?MkPsV2FPT0WU
Calu-6MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;i[GlEPTB;MT63N{BvVQ>?NUj6eW55W0GQR1XS
HELMljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLIVYhyUUN3ME2xMlc6KG6PNVjmTpFJW0GQR1XS
CAL-33NXv6eHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fafWlEPTB;MT64PUBvVQ>?NVvt[lB3W0GQR1XS
HSC-3MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTFwOUGgcm0>MW\TRW5ITVJ?
KU812MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jiUWlEPTB;MT65NUBvVQ>?M3fUS3NCVkeHUh?=
EB2M{fNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTUZmlkUUN3ME2yMlAyKG6PNYDRepZSW0GQR1XS
SRMn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPVbGdKSzVyPUKuNVIhdk1?NGnLWVVUSU6JRWK=
NCI-H2087MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:1U21oUUN3ME2yMlE1KG6PNGfa[pRUSU6JRWK=
H4NWjLd4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzMO4I{UUN3ME2yMlE5KG6PNUPRO2RwW0GQR1XS
EW-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XieWlEPTB;Mj6yNkBvVQ>?M{LDZnNCVkeHUh?=
MC-IXCM3nQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJwMk[gcm0>NVLRN3U{W0GQR1XS
NCI-H727MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e1R2lEPTB;Mj61NUBvVQ>?MonOV2FPT0WU
MRK-nu-1Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjrSXhTUUN3ME2yMlU4KG6PNX7K[VczW0GQR1XS
COLO-668NHPV[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorjTWM2OD1{Lk[2JI5ONUDQZ5RRW0GQR1XS
CGTH-W-1M1XvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjMbYVKSzVyPUKuO|Ihdk1?MVXTRW5ITVJ?
CHP-212NEHsXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTJwN{Wgcm0>MmnHV2FPT0WU
GI-1Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJwN{[gcm0>NFzlb5lUSU6JRWK=
HCC1806MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLWTWM2OD1{LkmxJI5ONWHqbXRkW0GQR1XS
HLEMlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DpRmlEPTB;MzDuUS=>MWfTRW5ITVJ?
HSC-2NEf1To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz3OY1KSzVyPUOuNFMhdk1?M4jzZXNCVkeHUh?=
DMS-273MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXFPVdKSzVyPUOuNFchdk1?MlzSV2FPT0WU
DU-4475NVvvN|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHkVZNKSzVyPUOuNVQhdk1?NEm0TodUSU6JRWK=
LXF-289Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\tdWlEPTB;Mz6zNUBvVQ>?MmS5V2FPT0WU
PANC-03-27NHnYflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7ZTWM2OD1|LkWxJI5OMW\TRW5ITVJ?
GAMGNYHYNXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTMTWM2OD1|Lke0JI5OMWDTRW5ITVJ?
NCI-H522M4rzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmOwTWM2OD12LkO0JI5OMXzTRW5ITVJ?
SW626NIfrPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV[zV5lyUUN3ME20MlQ3KG6PMmLCV2FPT0WU
HT-144M4PzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mni4TWM2OD12LkmyJI5OMXLTRW5ITVJ?
MEL-HOMnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUS0S5RoUUN3ME21MlE3KG6PNIPIW3pUSU6JRWK=
BE-13M{noOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTVwMkGgcm0>NGTi[INUSU6JRWK=
VA-ES-BJMlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTVwMk[gcm0>MnniV2FPT0WU
NCI-H441NH3Zc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\jboVKSzVyPUWuOkBvVQ>?NHnvXGZUSU6JRWK=
KP-4NFqxeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3W5WGlEPTB;NT62NUBvVQ>?MnfxV2FPT0WU
LoVoMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3yTWM2OD13LkexJI5OMoLaV2FPT0WU
HT-1080MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljzTWM2OD13LkizJI5OMlf0V2FPT0WU
GB-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTJTWM2OD13Lki0JI5OMYDTRW5ITVJ?
IA-LMMljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC5NVFKSzVyPUWuPVEhdk1?NFTmWlFUSU6JRWK=
8-MG-BAMmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoruTWM2OD13LkmzJI5ONF3lNnZUSU6JRWK=
SK-HEP-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjLT|lKSzVyPU[uNVQhdk1?NUTD[Xh2W0GQR1XS
697NXzselVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmOzTWM2OD14LkK1JI5ONWLRNGtFW0GQR1XS
KYSE-450MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTZwM{Kgcm0>MYrTRW5ITVJ?
HCC2998NGC5d5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTqTWM2OD14LkO0JI5OM3XaW3NCVkeHUh?=
HD-MY-ZNUDieYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2OyS2lEPTB;Nj62PEBvVQ>?M1HWXHNCVkeHUh?=
OS-RC-2Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTZwNkigcm0>Mk\MV2FPT0WU
SF126MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTdwMEWgcm0>Ml\2V2FPT0WU
Ca-SkiM1[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTdwMEmgcm0>M{n0RXNCVkeHUh?=
NCI-H358M1\UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\XdHdKSzVyPUeuNVYhdk1?M1fSe3NCVkeHUh?=
J82MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLHcIFKSzVyPUeuOFEhdk1?MYPTRW5ITVJ?
NCI-H2342MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1niPGlEPTB;Nz62N{BvVQ>?MnyyV2FPT0WU
OVCAR-8Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTdwOTDuUS=>M3vwZ3NCVkeHUh?=
TE-8NYLMVZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O2VGlEPTB;ODDuUS=>MnvXV2FPT0WU
ETK-1Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljtTWM2OD16LkC4JI5OMU\TRW5ITVJ?
HAL-01M1O5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRThwMjDuUS=>MUPTRW5ITVJ?
KYSE-150M3PTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEP1TnhKSzVyPUiuOFchdk1?M{DLO3NCVkeHUh?=
NCI-H810NXHjRYNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTLW|ZKSzVyPUiuOVYhdk1?Mmm4V2FPT0WU
ONS-76Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWmycG1sUUN3ME24MlY5KG6PNUC5WpZqW0GQR1XS
NMC-G1M3;yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRThwN{[gcm0>MVnTRW5ITVJ?
C3AM{Oy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLxTWM2OD16Lki0JI5OMVPTRW5ITVJ?
PA-1NGLqT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TWbWlEPTB;OD65PUBvVQ>?M133bXNCVkeHUh?=
SH-4Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTlwMEKgcm0>M2P2N3NCVkeHUh?=
EFO-27M33wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHSTWM2OD17LkC1JI5ONUHEdmkyW0GQR1XS
CAPAN-1NX3RW2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfxUZdyUUN3ME25MlI{KG6PMXTTRW5ITVJ?
DU-145NVWyUItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTlwMkmgcm0>NILnXHVUSU6JRWK=
A101DNHvLOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvvTWM2OD17LkO3JI5OMWPTRW5ITVJ?
ST486MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPMNlZGUUN3ME25MlQyKG6PMX3TRW5ITVJ?
NCI-H1437MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXO1T5lKUUN3ME25MlQzKG6PMoPoV2FPT0WU
HGC-27MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\aTWM2OD17Lk[gcm0>M1LCfXNCVkeHUh?=
8305CNFPzVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlviTWM2OD17Lk[0JI5OMkT4V2FPT0WU
OCUB-MM{Hq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFyLkCzJI5OM4PaZnNCVkeHUh?=
COLO-679MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInVRnNKSzVyPUGwMlA4KG6PMknjV2FPT0WU
Detroit562NEnsTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonrTWM2OD1zMD60NkBvVQ>?NYD5Z21RW0GQR1XS
A204MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\TSGQ6UUN3ME2xNU4yPiCwTR?=Mnm5V2FPT0WU
NCI-H1734MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fEfWlEPTB;MUGuNlkhdk1?NHLKNllUSU6JRWK=
MC-CARM2fKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVy0fVYxUUN3ME2xNU42QCCwTR?=MYXTRW5ITVJ?
NCI-H2170M3y0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDJTWM2OD1zMT65O{BvVQ>?Mlr3V2FPT0WU
NCI-SNU-5MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTF{LkGzJI5OMWDTRW5ITVJ?
HCE-TM3f2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF{LkSyJI5ONGXoeldUSU6JRWK=
KYSE-180M1LFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{izWWlEPTB;MUKuPFEhdk1?MlPtV2FPT0WU
C8166M1;zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37wVmlEPTB;MUOuNFghdk1?Ml;XV2FPT0WU
NCI-H460MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[1TWM2OD1zMz61OEBvVQ>?NU\rUIZiW0GQR1XS
SNU-449NVjlSoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofqTWM2OD1zMz63O{BvVQ>?M1KxNnNCVkeHUh?=
MDA-MB-468M1fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TKWmlEPTB;MUSuNVIhdk1?MULTRW5ITVJ?
COR-L23M1X1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\ITWM2OD1zND6xN{BvVQ>?NHX3c2FUSU6JRWK=
CTV-1MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1G4WWlEPTB;MUSuNVQhdk1?M3Xwd3NCVkeHUh?=
BL-41NH7zbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ThNmlEPTB;MUSuN|chdk1?MlXxV2FPT0WU
IGR-1NVHlNZNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi2emVvUUN3ME2xOE41OiCwTR?=MnXLV2FPT0WU
TK10NIfMSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrsTWM2OD1zND60PUBvVQ>?MVzTRW5ITVJ?
REHNITDenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\nTWM2OD1zND61NUBvVQ>?NYTid2oxW0GQR1XS
LU-139Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzxeI5KSzVyPUG0MlU6KG6PM4fkdnNCVkeHUh?=
KP-N-YSM{[1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrNTWM2OD1zND65O{BvVQ>?MYTTRW5ITVJ?
PANC-10-05Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\2TWM2OD1zNT6zPEBvVQ>?NELIeHRUSU6JRWK=
HL-60M1zoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnzZm1sUUN3ME2xOU43QSCwTR?=M1TUZXNCVkeHUh?=
T84MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37Ob2lEPTB;MUWuPVYhdk1?NYexTVI6W0GQR1XS
RPMI-8226M1:1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfi[Go1UUN3ME2xOk4xOiCwTR?=MUjTRW5ITVJ?
UM-UC-3MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDpTWM2OD1zNj6xOkBvVQ>?NYXxOVVnW0GQR1XS
TE-10NHeycnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS4UZpKSzVyPUG2MlIyKG6PMXzTRW5ITVJ?
CAL-148MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF5LkKzJI5OM2joTnNCVkeHUh?=
BV-173Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vXTmlEPTB;MUeuNlchdk1?MVnTRW5ITVJ?
Calu-3M1yyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jpT2lEPTB;MUeuNlkhdk1?MnHyV2FPT0WU
RPMI-2650MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmL2TWM2OD1zNz61PUBvVQ>?MmXpV2FPT0WU
MKN45M2P0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTF5LkezJI5ONYX5dZltW0GQR1XS
NUGC-3MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TzO2lEPTB;MUiuN|Qhdk1?MoWwV2FPT0WU
NCI-H520Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVT6U45sUUN3ME2xPE44PyCwTR?=M2XaRnNCVkeHUh?=
CCRF-CEMNXLUcGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\jTWM2OD1zOD64OUBvVQ>?MmfXV2FPT0WU
NCI-H2405NWjoc|JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHmTWM2OD1zOT6xJI5OM13uXHNCVkeHUh?=
ES7MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDkfotKSzVyPUG5Mlc3KG6PNIX1XHNUSU6JRWK=
BPH-1NYLCXmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEe2RVJKSzVyPUKwMlI5KG6PM{XYR3NCVkeHUh?=
SASNYTH[YF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jHfGlEPTB;MkCuOUBvVQ>?MWDTRW5ITVJ?
HuCCT1NEm5R|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTJyLkW4JI5ONEfXRZpUSU6JRWK=
LOUCYMn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfz[olKSzVyPUKwMlY3KG6PMmPMV2FPT0WU
NCI-H292M1fyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mon3TWM2OD1{MD63PUBvVQ>?MWrTRW5ITVJ?
G-361M{HVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXhUpVMUUN3ME2yNU4xPyCwTR?=M{PPWHNCVkeHUh?=
M059JMnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fxdmlEPTB;MkGuNFghdk1?MXLTRW5ITVJ?
NCI-H1651NFfR[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUexcIhvUUN3ME2yNU4yOSCwTR?=NWT1[21JW0GQR1XS
KALS-1NYOz[o1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLuO|FKSzVyPUKxMlM6KG6PM2XISXNCVkeHUh?=
DJM-1NEHNNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJzLkW5JI5OMmrRV2FPT0WU
AU565NVi0R3lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17ONmlEPTB;MkGuPFMhdk1?NFLIVmtUSU6JRWK=
HCC38NEOzfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LRc2lEPTB;MkGuPVUhdk1?M2HVN3NCVkeHUh?=
U251MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGewSY5KSzVyPUKyMlI4KG6PNIDxNFdUSU6JRWK=
ABC-1MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7FdYdKSzVyPUKyMlY2KG6PMnH0V2FPT0WU
SK-NEP-1NXfQb2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJ{LkmzJI5OMWHTRW5ITVJ?
CESSNHW1O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml6xTWM2OD1{Mz6xPUBvVQ>?MlXOV2FPT0WU
MIA-PaCa-2M3[1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUm4W|B4UUN3ME2yN{4{PiCwTR?=MX\TRW5ITVJ?
SUP-T1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvNTWM2OD1{Mz60O{BvVQ>?MkfRV2FPT0WU
L-428M1m2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHCTWM2OD1{Mz62NkBvVQ>?MUDTRW5ITVJ?
SW954NH30NWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJ|Lk[4JI5ONGKzVHNUSU6JRWK=
HO-1-N-1NILOdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3FSZZbUUN3ME2yN{44PyCwTR?=Ml[2V2FPT0WU
CHP-126MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn5UmlSUUN3ME2yOE4yPCCwTR?=MVLTRW5ITVJ?
HMV-IIMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfr[opKSzVyPUK0MlM1KG6PMUnTRW5ITVJ?
NB10NELHUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;seWlEPTB;MkSuN|chdk1?M4i2dXNCVkeHUh?=
A172Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEi2Z5FKSzVyPUK0MlcyKG6PM4\NZXNCVkeHUh?=
MONO-MAC-6NFjrV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3T5c2lEPTB;MkSuPFQhdk1?M1PuSHNCVkeHUh?=
NCI-H1650NFjyW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojFTWM2OD1{NT60JI5OMVHTRW5ITVJ?
NH-12Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;n[GlEPTB;MkWuOUBvVQ>?M4LJUXNCVkeHUh?=
ML-2MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;tNGVKSzVyPUK1Mlc1KG6PNYrhSGtGW0GQR1XS
MZ2-MELMl7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2OzWmlEPTB;Mk[uNlIhdk1?NXy5c4lKW0GQR1XS
COLO-684MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUX3UoxXUUN3ME2yOk41OSCwTR?=M3fISHNCVkeHUh?=
HuP-T4NYDw[IZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWi3U3B{UUN3ME2yO{4{KG6PNEDHS|RUSU6JRWK=
SW837M3jaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH4WJNiUUN3ME2yO{43OiCwTR?=NV3Wc|ZMW0GQR1XS
MDA-MB-231NIfSSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXmU|NKSzVyPUK3Mlc5KG6PMYnTRW5ITVJ?
KYSE-140NFPoZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT2TWM2OD1{Nz65NUBvVQ>?NYDFS4t2W0GQR1XS
NOMO-1NVOxTJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XYTWlEPTB;MkiuOlghdk1?M1jYWXNCVkeHUh?=
GP5dNUW1eZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoK0TWM2OD1{OD63NkBvVQ>?NWLnSJM4W0GQR1XS
COR-L105NGKwNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XucGlEPTB;MkmuOFIhdk1?MkHWV2FPT0WU
LS-411NMlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\FVHh2UUN3ME2yPU45QCCwTR?=MkLuV2FPT0WU
NYMkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\QelhKSzVyPUOwMlE5KG6PM1vNW3NCVkeHUh?=
NCI-H2030M2T6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzifHA3UUN3ME2zNE41PSCwTR?=NIX3cJBUSU6JRWK=
CCF-STTG1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXK1VXgzUUN3ME2zNU41OiCwTR?=M{LUbXNCVkeHUh?=
NCI-H1703MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fndGlEPTB;M{GuO|ghdk1?MUnTRW5ITVJ?
TURNIX1UIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mli1TWM2OD1|Mj6wN{BvVQ>?NED2VFhUSU6JRWK=
NOS-1NEfyN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITCW3ZKSzVyPUOyMlQ1KG6PNYL2VpROW0GQR1XS
A2058NWfRPWxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7iZmtKSzVyPUOyMlg{KG6PNFj5WmlUSU6JRWK=
LCLC-103HMonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjFTWM2OD1|Mz6yOUBvVQ>?MVjTRW5ITVJ?
NCI-H510AMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTN|LkK3JI5ONVz0e4p2W0GQR1XS
BC-1NH7qNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTN|Lke3JI5ONEDQd4pUSU6JRWK=
SK-CO-1M1HUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXUd5ZKSzVyPUO0MlAyKG6PNGnzU49USU6JRWK=
A673M1PE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLQXoZIUUN3ME2zOE4yPyCwTR?=NVnZcY03W0GQR1XS
VM-CUB-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTN2Lk[5JI5ONUnOVJNVW0GQR1XS
HHMn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTN3LkC2JI5ONF20SFNUSU6JRWK=
CAL-27NX3TNVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17YbGlEPTB;M{WuNVYhdk1?MUfTRW5ITVJ?
NEC8MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTN3LkO3JI5ONEDwS4JUSU6JRWK=
BxPC-3MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHDOIdKSzVyPUO2MlkyKG6PNH3xdFdUSU6JRWK=
SNB75MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\MTWM2OD1|Nz6yOEBvVQ>?MYHTRW5ITVJ?
NB13NIj1UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1naVGlEPTB;M{iuNlMhdk1?NF\odINUSU6JRWK=
SK-OV-3NGrESFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTN6Lke0JI5ONHSwRZVUSU6JRWK=
ME-180MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInIOmVKSzVyPUO4Mlghdk1?NXjkXIVTW0GQR1XS
JiyoyeP-2003M1;FWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mli4TWM2OD1|OT6zPEBvVQ>?MWnTRW5ITVJ?
LU-134-ANGPYTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\sSGlEPTB;NECuNFIhdk1?Mmf5V2FPT0WU
LS-123MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfHVJBKSzVyPUSwMlI5KG6PNVXhfWdmW0GQR1XS
COLO-800MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjRTWM2OD12MD61OkBvVQ>?M2O4S3NCVkeHUh?=
LB831-BLCMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTRzLki1JI5OM4fidHNCVkeHUh?=
NCI-H747M4jVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTR{LkK4JI5OM4i2dXNCVkeHUh?=
MZ7-melMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XZZ2lEPTB;NEKuOlYhdk1?MWrTRW5ITVJ?
GT3TKBNH20c|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTR{LkeyJI5ONGPWUGVUSU6JRWK=
MOLT-16NYjMdWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDaTWM2OD12Mz6wOUBvVQ>?MWHTRW5ITVJ?
23132-87MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTR|LkC1JI5ONGDyOFdUSU6JRWK=
PF-382Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlixTWM2OD12ND6yNkBvVQ>?NYnxW45zW0GQR1XS
ES3MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;yemZoUUN3ME20OE43KG6PNEfQXYlUSU6JRWK=
SW756NIrvVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\0W2lEPTB;NEWuNVQhdk1?M1L4bXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02538432 Not yet recruiting Prostate Cancer|Non-Small Cell Lung Cancer|Breast Cancer University of Maryland January 2017 Phase 2
NCT02767557 Not yet recruiting Unresectable Pancreatic Carcinoma Herlev Hospital|Celgene|Roche Pharma AG October 2016 Phase 2
NCT02806687 Not yet recruiting Pancreatic Adenocarcinoma University Hospital, Toulouse|BIOTHERAPY department of th  ...more University Hospital, Toulouse|BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse|InvivoGen Therapeutics October 2016 Phase 2
NCT02741388 Not yet recruiting B-cell Lymphoma The Lymphoma Academic Research Organisation|Karyopharm Th  ...more The Lymphoma Academic Research Organisation|Karyopharm Therapeutics, Inc September 2016 Phase 1
NCT02723838 Not yet recruiting Muscle-invasive Transitional Cell Carcinoma of the Bladder Oncolytics Biotech September 2016 Phase 1

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water 16 mg/mL warming (60.79 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo water 16mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Frequently Asked Questions

  • Question 1
    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

    Answer: Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us